AI Engines For more Details: Perplexity Kagi Labs You
Treatment of Psoriasis: Anthralin is effective in reducing the symptoms of psoriasis by slowing down the excessive growth of skin cells and reducing inflammation. It is commonly applied to the affected areas of the skin as a cream, ointment, or solution.
Anti-inflammatory Properties: Anthralin has anti-inflammatory effects that help alleviate the redness, swelling, and itching associated with psoriasis lesions. It works by suppressing the immune response and inhibiting the release of inflammatory mediators in the skin.
Keratolytic Action: Anthralin has keratolytic properties, meaning it helps to soften and remove the thickened, scaly patches of skin characteristic of psoriasis. By promoting the shedding of dead skin cells, it helps to smooth the skin's surface and reduce plaque formation.
Staining of Skin and Clothing: Anthralin may cause temporary discoloration of the skin and clothing due to its brownish-red color. This staining is usually reversible and fades over time once treatment is discontinued.
Skin Irritation: Anthralin can cause skin irritation, such as redness, itching, and burning, especially when used at higher concentrations or for prolonged periods. It is important to follow the prescribed dosage and application instructions to minimize the risk of adverse effects.
Photosensitivity: Anthralin-treated skin may become more sensitive to sunlight, increasing the risk of sunburn. Patients using anthralin should avoid prolonged sun exposure and use sunscreen to protect their skin from UV radiation.
Staining of Nails and Hair: Anthralin can also stain the nails and hair if it comes into contact with them during application. This staining is usually temporary and can be removed with washing.
Long-Term Use: Anthralin is generally safe for long-term use in the treatment of psoriasis, but regular monitoring by a healthcare professional is recommended to assess its effectiveness and monitor for any potential side effects.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Akkermansiaceae | family | Decreases |
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Ruminococcus | genus | Decreases |
| 0 | 1 | Agathobacter | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Clostridioides | genus | Decreases |
| 0 | 1 | Collinsella | genus | Decreases |
| 0 | 1 | Coprococcus | genus | Decreases |
| 0 | 1 | Eggerthella | genus | Decreases |
| 0 | 1 | Lachnospira | genus | Decreases |
| 0 | 1 | Lacrimispora | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Odoribacter | genus | Decreases |
| 0 | 1 | Phocaeicola | genus | Decreases |
| 0 | 1 | Veillonella | genus | Decreases |
| 0 | 1 | Clostridium | genus | Decreases |
| 0 | 1 | Segatella | genus | Decreases |
| 0 | 1 | Enterocloster | genus | Decreases |
| 0 | 1 | Blautia | genus | Decreases |
| 0 | 1 | Thomasclavelia | genus | Decreases |
| 1 | 0 | Akkermansia | genus | Decreases |
| 0 | 1 | Lacticaseibacillus | genus | Decreases |
| 0 | 1 | Clostridium perfringens A | no rank | Decreases |
| 0 | 1 | Clostridium perfringens C | no rank | Decreases |
| 0 | 1 | Clostridium perfringens CPE | no rank | Decreases |
| 0 | 1 | environmental samples | no rank | Decreases |
| 0 | 1 | unclassified Akkermansia | no rank | Decreases |
| 0 | 1 | Clostridium perfringens D | no rank | Decreases |
| 0 | 1 | Clostridium perfringens B | no rank | Decreases |
| 0 | 1 | Clostridium perfringens E | no rank | Decreases |
| 1 | 0 | Ruminococcus bromii | species | Decreases |
| 1 | 0 | Agathobacter rectalis | species | Decreases |
| 1 | 0 | Bacteroides fragilis | species | Decreases |
| 1 | 0 | Bacteroides uniformis | species | Decreases |
| 1 | 0 | Blautia obeum | species | Decreases |
| 1 | 0 | Clostridioides difficile | species | Decreases |
| 1 | 0 | Clostridium perfringens | species | Decreases |
| 1 | 0 | Collinsella aerofaciens | species | Decreases |
| 1 | 0 | Coprococcus comes | species | Decreases |
| 1 | 0 | Eggerthella lenta | species | Decreases |
| 1 | 0 | Enterocloster bolteae | species | Decreases |
| 1 | 0 | Lachnospira eligens | species | Decreases |
| 1 | 0 | Mediterraneibacter gnavus | species | Decreases |
| 1 | 0 | Odoribacter splanchnicus | species | Decreases |
| 1 | 0 | Parabacteroides merdae | species | Decreases |
| 1 | 0 | Phocaeicola vulgatus | species | Decreases |
| 1 | 0 | Segatella copri | species | Decreases |
| 1 | 0 | Thomasclavelia ramosa | species | Decreases |
| 1 | 0 | Veillonella parvula | species | Decreases |
| 1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
| 1 | 0 | Lacrimispora saccharolytica | species | Decreases |
| 1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
| 0 | 1 | Akkermansia massiliensis | species | Decreases |
| 0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
| 1 | 0 | Akkermansia muciniphila | species | Decreases |
| 0 | 1 | Akkermansia glycaniphila | species | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.4 | 0.4 | |
| Acne | 0.6 | 0.6 | |
| ADHD | 2.2 | 0.6 | 2.67 |
| Age-Related Macular Degeneration and Glaucoma | 0.4 | -0.4 | |
| Allergic Rhinitis (Hay Fever) | 1.7 | 0 | 0 |
| Allergies | 4.7 | 2.4 | 0.96 |
| Allergy to milk products | 1.4 | 0.7 | 1 |
| Alopecia (Hair Loss) | 0.5 | 0.5 | |
| Alzheimer's disease | 3.5 | 3.6 | -0.03 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.9 | 0.4 | 3.75 |
| Ankylosing spondylitis | 2 | 1.5 | 0.33 |
| Anorexia Nervosa | 1.1 | 2.4 | -1.18 |
| Antiphospholipid syndrome (APS) | 0.4 | 0.4 | |
| Asthma | 2.7 | 0.7 | 2.86 |
| Atherosclerosis | 1.5 | 1.4 | 0.07 |
| Atrial fibrillation | 2.9 | 1.9 | 0.53 |
| Autism | 8.3 | 5.7 | 0.46 |
| Autoimmune Disease | 0.2 | -0.2 | |
| Barrett esophagus cancer | 0.3 | 0.3 | |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.9 | 0.9 | |
| Bipolar Disorder | 1.5 | 1.2 | 0.25 |
| Brain Trauma | 0.3 | 0.6 | -1 |
| Breast Cancer | 0.3 | 0.3 | 0 |
| Cancer (General) | 0.6 | 1.1 | -0.83 |
| Carcinoma | 2 | 1.7 | 0.18 |
| Celiac Disease | 2.1 | 2 | 0.05 |
| Cerebral Palsy | 0.8 | 0.7 | 0.14 |
| Chronic Fatigue Syndrome | 4.6 | 4.9 | -0.07 |
| Chronic Kidney Disease | 2.8 | 1.5 | 0.87 |
| Chronic Lyme | 0.6 | 0.3 | 1 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.6 | 0.9 | -0.5 |
| Chronic Urticaria (Hives) | 0.5 | 1.3 | -1.6 |
| Coagulation / Micro clot triggering bacteria | 0.4 | 0.4 | 0 |
| Cognitive Function | 1.9 | 0.5 | 2.8 |
| Colorectal Cancer | 5 | 1.4 | 2.57 |
| Constipation | 1.5 | 0.7 | 1.14 |
| Coronary artery disease | 1.5 | 2.5 | -0.67 |
| COVID-19 | 6.9 | 8.4 | -0.22 |
| Crohn's Disease | 5.3 | 4.2 | 0.26 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 0.4 | -0.4 | |
| deep vein thrombosis | 1.4 | 0.6 | 1.33 |
| Denture Wearers Oral Shifts | 0.6 | 0.6 | |
| Depression | 7.1 | 6.4 | 0.11 |
| Eczema | 1.1 | 0.8 | 0.38 |
| Endometriosis | 1.1 | 1.5 | -0.36 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 1.9 | 1.5 | 0.27 |
| erectile dysfunction | 1.7 | 1.7 | |
| Fibromyalgia | 2.3 | 2.3 | 0 |
| Functional constipation / chronic idiopathic constipation | 3.3 | 2.8 | 0.18 |
| gallstone disease (gsd) | 2.6 | 0 | 0 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.5 | 0.9 | 0.67 |
| Generalized anxiety disorder | 1.6 | 0.8 | 1 |
| giant cell arteritis | 0.2 | -0.2 | |
| Gout | 0.6 | 0.8 | -0.33 |
| Graves' disease | 1.6 | 1.6 | 0 |
| Gulf War Syndrome | 0.6 | 1.1 | -0.83 |
| Halitosis | 0.6 | 0.6 | |
| Hashimoto's thyroiditis | 1.6 | 0.6 | 1.67 |
| Heart Failure | 3.3 | 1.1 | 2 |
| hemorrhagic stroke | 0.4 | 0.4 | |
| Hidradenitis Suppurativa | 0.6 | 0.3 | 1 |
| High Histamine/low DAO | 0.8 | 0.3 | 1.67 |
| hypercholesterolemia (High Cholesterol) | 0.5 | 0.1 | 4 |
| hyperglycemia | 1.2 | 0.9 | 0.33 |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | 0 |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 2.4 | 3 | -0.25 |
| Hypothyroidism | 0 | 0.7 | 0 |
| Hypoxia | 1.5 | 0.6 | 1.5 |
| IgA nephropathy (IgAN) | 1.3 | 3.9 | -2 |
| Inflammatory Bowel Disease | 6.5 | 6.2 | 0.05 |
| Insomnia | 1 | 1.7 | -0.7 |
| Intelligence | 1.4 | 0.6 | 1.33 |
| Intracranial aneurysms | 1.2 | 0.6 | 1 |
| Irritable Bowel Syndrome | 4.1 | 3.7 | 0.11 |
| ischemic stroke | 1.5 | 0.6 | 1.5 |
| Liver Cirrhosis | 4 | 2.1 | 0.9 |
| Long COVID | 6 | 5.5 | 0.09 |
| Low bone mineral density | 0.6 | -0.6 | |
| Lung Cancer | 0.5 | -0.5 | |
| Mast Cell Issues / mastitis | 0.6 | -0.6 | |
| ME/CFS with IBS | 0.8 | 1.5 | -0.88 |
| ME/CFS without IBS | 1.7 | 0.4 | 3.25 |
| Menopause | 0 | 0 | |
| Metabolic Syndrome | 4.3 | 4.1 | 0.05 |
| Mood Disorders | 7.7 | 6.1 | 0.26 |
| multiple chemical sensitivity [MCS] | 0.3 | 0.1 | 2 |
| Multiple Sclerosis | 3.8 | 4.8 | -0.26 |
| Multiple system atrophy (MSA) | 0.1 | 0.4 | -3 |
| myasthenia gravis | 0.2 | -0.2 | |
| neuropathic pain | 0.3 | 1.6 | -4.33 |
| Neuropathy (all types) | 0.5 | 1.6 | -2.2 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3 | 2.9 | 0.03 |
| NonCeliac Gluten Sensitivity | 1.1 | 0.3 | 2.67 |
| Obesity | 5.7 | 5.2 | 0.1 |
| obsessive-compulsive disorder | 4.9 | 2.5 | 0.96 |
| Osteoarthritis | 2.4 | 0.6 | 3 |
| Osteoporosis | 1.4 | 0.5 | 1.8 |
| pancreatic cancer | 0.3 | 0.3 | |
| Parkinson's Disease | 5.8 | 5 | 0.16 |
| Polycystic ovary syndrome | 5.4 | 1.9 | 1.84 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
| Premenstrual dysphoric disorder | 0.4 | 0.4 | 0 |
| primary biliary cholangitis | 0.3 | 1.1 | -2.67 |
| Primary sclerosing cholangitis | 1.8 | 2.7 | -0.5 |
| Psoriasis | 2.2 | 2.4 | -0.09 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.8 | 3 | 0.6 |
| Rosacea | 0.3 | 0.2 | 0.5 |
| Schizophrenia | 4.9 | 2.3 | 1.13 |
| scoliosis | 0.3 | 0.9 | -2 |
| Sjögren syndrome | 2.3 | 1.7 | 0.35 |
| Sleep Apnea | 1 | 1.3 | -0.3 |
| Slow gastric motility / Gastroparesis | 0.9 | 0.9 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.1 | 1.1 | |
| Stress / posttraumatic stress disorder | 0.9 | 2 | -1.22 |
| Systemic Lupus Erythematosus | 3.4 | 1.5 | 1.27 |
| Tic Disorder | 1.2 | 0.9 | 0.33 |
| Tourette syndrome | 0 | 0.3 | 0 |
| Type 1 Diabetes | 2.8 | 1.7 | 0.65 |
| Type 2 Diabetes | 5.9 | 4.9 | 0.2 |
| Ulcerative colitis | 4.7 | 5.3 | -0.13 |
| Unhealthy Ageing | 4.2 | 1.6 | 1.63 |
| Vitiligo | 1.9 | 1.3 | 0.46 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
